Peginterferon alpha-2a

Therapeutic indications

Peginterferon alpha-2a is indicated for:

Chronic hepatitis B

Population group: only adults (18 years old or older)

Peginterferon alpha-2a is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAgnegative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic hepatitis C (CHC)

Population group: only adults (18 years old or older)

Peginterferon alpha-2a is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

HBeAg-positive chronic hepatitis B (CHB)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Peginterferon alpha-2a is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.

When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Positive HCV-RNA chronic hepatitis C

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Peginterferon alpha-2a in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.

When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Peginterferon alpha-2a is contraindicated in the following cases:

Telbivudine

Telbivudine

Autoimmune hepatitis

Autoimmune hepatitis

Severe hepatic dysfunction, decompensated cirrhosis of the liver

at least one of
Hepatic failure stage IV
Decompensated cirrhosis of liver

Cardiac disease

Heart disease

HIV-HCV with cirrhosis and a Child-Pugh score ≥6

Human immunodeficiency virus infection and additionally Viral hepatitis C and additionally Cirrhosis of liver

Severe depression, suicidal ideation, suicidal attempt

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

at least one of
Severe depression
Suicidal ideation
Suicide attempt

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: PEGASYS Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈